The AACR Journal Editors are proud to present the Cancer Cell Cycle and Therapeutic Response article collection highlighting the emerging areas of cancer research covered at the Cancer Cell Cycle - Tumor Progression and Therapeutic Response conference. Get complimentary access this collection anytime, anywhere.

Read the Clinical Cancer Research article, “Safety of VX15/2503 in patients with advanced solid tumors”. The authors evaluated the safety and tolerability of the anti-semaphorin 4D antibody VX15/2503 in a first-in-human study. Treatment-related adverse events were primarily grade 1 or 2; one patient (15 mg/kg) experienced a grade 3 DLT. No MTD was determined. Complete cellular SEMA4D saturation was generally observed at serum antibody concentrations ≥0.3 µg/mL, resulting in decreased ligand expression. One patient (20 mg/kg) experienced a PR and 27 patients exhibited SD for ≥8 weeks; subjects with elevated B /T lymphocytes exhibited longer progression-free survival. Preclinical studies suggest that combining VX15/2503 with immune-modulating agents may improve the clinical activity of checkpoint blockade inhibitors..

This year marks 100 years of scientific publishing for the AACR. Help us celebrate by clicking "like" on your favorite images in this album to vote for your favorite AACR journal cover art: One like = one vote. We'll feature the top vote-getters on our website and in a printed calendar which will be distributed at the AACR Annual Meeting 2016.